2nd Edition of
International Vaccines Congress
Event Book
Event program
Scientific Program
About
Magnus Group takes honor and great opportunity to invite you to the “2nd Edition of International Vaccines Congress” (IVC 2022) scheduled during October 19-20, 2022 (Virtual Event). IVC 2022 strives to provide a meaningful theme of “Synergy to Rehabilitate Innovations in Vaccine Research and Development” and offers a great international multidisciplinary platform bringing together the professionals, researchers and world class scientists from Vaccine researchers and potential investigators. We encourage you to take part in this conference as there will be Keynote address to Oral and Poster presentations with the discussions focused on diversified scientific sessions ranging from basic cell science to advanced innovations in the field of Vaccinations with novel and sophisticated applications for the betterment of healthcare.
Scientific Committee Members
Vincenzo Alfano
University of Napoli Parthenope, Italy
Sudhakar Bangera
Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, BrazilSpeakers
Deborah Hilton
Deborah Hilton Statistics Online, Australia
Sissy Therese Sonnleitner
Innsbruck Medical University, Austria
Christine Bricault
Sanofi Vaccines, United States
Yusuf Ziya Sener
Beypazarı State Hospital, Turkey
Angelo Tunin Chica Pergo
Faculty Of Medicine Of Itajuba, Brazil
Seyedeh Sajedeh Mousavi
Islamic Azad University, Iran (Islamic Republic of)
Solange Whegang Youdom
University of Dschang, Cameroon
Jamil M A S Obaid
Ibb University, YemenGallery
Reviews
Title : The need for separate regulations for prophylactic vaccines
Sudhakar Bangera, Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India
Title : Analytical transfer of COVID-19 recombinant vaccine between fiocruz and astrazeneca
Rosane Cuber Guimaraes, Bio-Manguinhos/ Fiocruz, Brazil
Title : Your vaccine attitude determines your altitude what are the determinants of attitude toward vaccination?
Vincenzo Alfano, University of Napoli Parthenope, Italy
Title : Therapeutic repositioning of the monoclonal antibodies itolizumab and nimotuzumab in COVID-19.
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Robust antibody-mediated protection against SARS-CoV-2 induced by NVX-CoV2373 subunit vaccine adjuvanted with matrix-M
Alex Zhu, University of Duisburg-Essen, United States
Title : Development and validation of a specific tool to assess vaccination hesitation during the COVID-19 pandemic
Angelo Tunin Chica Pergo, Faculty Of Medicine Of Itajuba, Brazil